Cancel anytime
Allakos Inc (ALLK)ALLK
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/02/2024: ALLK (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Profit: -68.75% | Upturn Advisory Performance 2 | Avg. Invested days: 32 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 10/02/2024 |
Type: Stock | Today’s Advisory: PASS |
Profit: -68.75% | Avg. Invested days: 32 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 10/02/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 55.44M USD |
Price to earnings Ratio - | 1Y Target Price 2.77 |
Dividends yield (FY) - | Basic EPS (TTM) -2.35 |
Volume (30-day avg) 364823 | Beta 1.15 |
52 Weeks Range 0.54 - 3.40 | Updated Date 10/1/2024 |
Company Size Small-Cap Stock | Market Capitalization 55.44M USD | Price to earnings Ratio - | 1Y Target Price 2.77 |
Dividends yield (FY) - | Basic EPS (TTM) -2.35 | Volume (30-day avg) 364823 | Beta 1.15 |
52 Weeks Range 0.54 - 3.40 | Updated Date 10/1/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -49.29% | Return on Equity (TTM) -121.54% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value -27499902 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.5 |
Shares Outstanding 88850704 | Shares Floating 59217223 |
Percent Insiders 2.33 | Percent Institutions 88.1 |
Trailing PE - | Forward PE - | Enterprise Value -27499902 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.5 | Shares Outstanding 88850704 | Shares Floating 59217223 |
Percent Insiders 2.33 | Percent Institutions 88.1 |
Analyst Ratings
Rating 3.12 | Target Price 9.92 | Buy 2 |
Strong Buy - | Hold 5 | Sell 1 |
Strong Sell - |
Rating 3.12 | Target Price 9.92 | Buy 2 | Strong Buy - |
Hold 5 | Sell 1 | Strong Sell - |
AI Summarization
Allakos Inc.: A Comprehensive Overview (as of November 2023)
Company Profile
Detailed History and Background:
- Founded in 2007 in Redwood City, California, by Dr. Michael Dillon and Dr. Adrian Hepner.
- Initial focus on developing therapies for chronic inflammatory diseases like allergic asthma.
- 2015: Completed a pivotal Phase III study for AK002 in atopic dermatitis.
- 2016: Public offering on NASDAQ, raising $97 million.
- 2023: Ongoing Phase III program for lirentelimab (AK002) in eosinophilic esophagitis (EoE).
Core Business Areas:
- Developing therapeutic antibodies targeting the immune system.
- Focus on inflammatory and allergic diseases like EoE, atopic dermatitis, and asthma.
- Utilizing a proprietary discovery platform – the Th2-inflammation Antibody Discovery and Development (Th2-iADD) platform.
Leadership Team:
- President & CEO: Dr. Maurice A. Zauderer, extensive experience in the pharmaceutical industry, including leadership at Genentech and Roche.
- Chief Medical Officer: Dr. Michael A. DeBaun, former VP Clinical Development & Medical Affairs at Dyax Corp.
- Other key executives with expertise in research, development, finance, and legal.
Top Products and Market Share
Top Products:
- Lirnelimab (AK002): Anti-IL-13 monoclonal antibody, currently in Phase III trials for EoE and atopic dermatitis.
- Eniflamilast (AK001): Pan-PDE4 inhibitor, previously in development for asthma but discontinued due to safety concerns.
Market Share:
- Lirnelimab has no direct competitors as it targets a novel pathway in EoE.
- For atopic dermatitis, competitors include dupilumab (Dupixent) by Regeneron and Sanofi, and tralokinumab (Adtralza) by LEO Pharma.
Product Performance and Market Reception:
- Early data from Phase III studies for EoE show lirentelimab to be safe and effective, with potential to be a first-in-class treatment.
- Initial market response has been positive, with analysts expecting strong sales potential upon approval.
Total Addressable Market
EoE: Estimated to be around 1 million patients in the U.S. and EU. Atopic Dermatitis: Affects around 10-20% of children and 1-3% of adults globally.
Financial Performance
Recent Financial Statements:
- Revenue: Primarily from collaborations and grants.
- Net Income: Currently negative due to R&D expenses.
- Profit Margins: Not yet profitable.
- EPS: Negative, reflecting R&D investments.
Year-over-Year Performance:
- Revenue has been increasing steadily due to progress in clinical trials and partnerships.
- Net losses have also been increasing, reflecting R&D investments.
Cash Flow and Balance Sheet:
- Current cash and equivalents: $218 million as of June 2023.
- Strong cash position to support ongoing clinical trials.
Dividends and Shareholder Returns
Dividend History:
- No dividend history as the company is not yet profitable.
Shareholder Returns:
- Stock price has fluctuated significantly based on clinical trial results and market sentiment.
- Overall, shareholder returns have been positive since the IPO.
Growth Trajectory
Historical Growth:
- Revenue has grown significantly in recent years due to clinical progress and collaborations.
- Net losses have also increased due to R&D investments.
Future Growth Projections:
- Analysts expect strong revenue growth upon potential approval and commercialization of lirentelimab.
- Future growth will depend on clinical trial outcomes, regulatory approvals, and market adoption.
Market Dynamics
Industry Overview:
- Growing market for treatments of inflammatory and allergic diseases.
- Increasing demand for novel and effective therapies with better safety profiles.
- Intense competition among pharmaceutical companies.
Company Positioning:
- Allakos holds a first-mover advantage with lirentelimab as a potential first-in-class treatment for EoE.
- The company needs to demonstrate the safety and efficacy of its products to achieve long-term success.
Competitors
Key Competitors:
- For EoE: None currently, but potential competitors include companies developing anti-IL-5 therapies.
- For atopic dermatitis: Regeneron, Sanofi, LEO Pharma, and others.
Market Share Percentages:
- Lirnelimab: No market share yet, as it is not yet approved.
- Competitors: Dupixent (Dupilumab) holds a significant market share in atopic dermatitis.
Competitive Advantages:
- First-mover advantage with lirentelimab for EoE.
- Proprietary Th2-iADD platform with potential for further pipeline development.
Disadvantages:
- Limited commercial experience.
- Dependence on a single drug candidate for near-term growth.
Potential Challenges and Opportunities
Key Challenges:
- Demonstrating safety and efficacy of lirentelimab in ongoing clinical trials.
- Obtaining regulatory approvals for lirentelimab in target markets.
- Achieving market adoption and competing with established players in atopic dermatitis.
Potential Opportunities:
- Expanding the use of lirentelimab into other indications beyond EoE and atopic dermatitis.
- Developing additional product candidates from the Th2-iADD platform.
- Partnering with larger pharmaceutical companies for commercialization and distribution.
Recent Acquisitions
No acquisitions have been made by Allakos Inc. in the past 3 years.
AI-Based Fundamental Rating
8 out of 10:
Strengths:
- Promising late-stage drug candidate with first-mover advantage.
- Strong cash position to support ongoing operations.
- Experienced leadership team with industry expertise.
Weaknesses:
- Limited commercial experience and dependence on a single drug candidate.
- Intense competition in the targeted markets.
Overall, Allakos Inc. is a promising company with a strong pipeline and potential for significant growth upon commercialization of lirentelimab. However, it faces challenges in a competitive market and needs to execute successfully on its clinical and commercialization plans.
Sources and Disclaimers
Sources:
- Allakos Inc. website (https://www.allakos.com/)
- SEC filings (https://www.sec.gov/edgar/search/)
- Analyst reports
- News articles
Disclaimer:
This information is provided for informational purposes only and should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allakos Inc
Exchange | NASDAQ | Headquaters | San Carlos, CA, United States |
IPO Launch date | 2018-07-19 | CEO & Director | Dr. Robert Alexander Ph.D. |
Sector | Healthcare | Website | https://www.allakos.com |
Industry | Biotechnology | Full time employees | 131 |
Headquaters | San Carlos, CA, United States | ||
CEO & Director | Dr. Robert Alexander Ph.D. | ||
Website | https://www.allakos.com | ||
Website | https://www.allakos.com | ||
Full time employees | 131 |
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.